Inhibrx Biosciences Quarterly Cash Flow Statement
NASDAQ: INBXHealthcareBiotechnologyUSD
95.01+2.25 (+2.43%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences free cash flow
In the quarter ended Jun 30, 2026, Inhibrx Biosciences generated -$29.9 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$29.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Inhibrx Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -36.65M | -33.44M | -32.83M | -35.26M | -28.65M | -43.31M | -47.87M | -43.86M | 1.86B | -78.71M | -93.60M | -51.79M |
| Net Income growth (YoY) | — | — | — | — | -101.54% | — | — | — | — | — | — | — |
| Depreciation & Amortization | 523.00K | 537.00K | 564.00K | 582.00K | 662.00K | 675.00K | 689.00K | 760.00K | 475.00K | 360.00K | 298.00K | 304.00K |
| Stock-Based Compensation | 3.10M | 2.65M | 2.74M | 3.17M | 2.77M | 2.45M | 2.98M | 2.96M | 46.17M | 6.40M | 6.43M | 6.53M |
| Change in Working Capital | 1.81M | -8.43M | -1.89M | -2.88M | -4.75M | 3.46M | -599.00K | 9.40M | 38.06M | 9.72M | 28.84M | -10.38M |
| Operating Cash Flow | -29.92M | -38.03M | -30.12M | -33.82M | -29.95M | -35.90M | -43.72M | -30.28M | -57.36M | -63.05M | -56.82M | -54.24M |
| Capital Expenditures | 0 | 0 | 0 | -10.00K | 0 | -21.00K | -16.00K | -247.00K | -1.22M | -1.12M | -3.44M | -811.00K |
| Investing Cash Flow | 0 | 0 | 0 | -7.00K | 0 | -21.00K | -16.00K | -247.00K | -1.22M | -1.12M | -3.44M | -811.00K |
| Financing Cash Flow | 1.60M | 75.46M | 1.25M | 352.00K | 0 | 99.84M | 0 | 0 | 32.95M | 38.73M | 860.00K | 199.89M |
| Net Change in Cash | -28.31M | 37.44M | -28.87M | -33.48M | -29.95M | 63.92M | -43.74M | -30.53M | -25.62M | -25.44M | -59.40M | 144.84M |
| Free Cash Flow | -29.92M | -38.03M | -30.12M | -33.83M | -29.95M | -35.92M | -43.74M | -30.53M | -58.57M | -64.17M | -60.26M | -55.06M |
This table shows 12 quarterly periods of Inhibrx Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow INBX's reporting calendar. What is a cash flow statement?